CMClarissa Masur

Clarissa Masur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clarissa Masur has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A 1% glycopyrronium bromide cream for topical treatment of severe primary axillary hyperhidrosis in adolescents: safety, local tolerability, systemic exposure and efficacy from an open‐label phase II study

    by Rolf‐Markus Szeimies, Ana Kilic, Hubert Reich, Birgit Berger, Erik Schulze Zur Wiesche, Leonie Litzka, Katharina Schramm, Susanne Heimstaedt‐Muskett, Clarissa Masur

    Summary: Background and objectives: Primary axillary hyperhidrosis (PAHH) results from dysregulation of the autonomic nervous system and typically begins during puberty. Treatment options for adolescents remain limited. This open‐label phase II study evaluated the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream over 8 weeks in adolescents with severe PAHH. Patients and methods: A total of 42 adolescents (23 male [55%] and 19 female [45%]; aged 12–17 years) applied the cream once daily for the first 4 weeks and thereafter as needed (at least twice weekly but no more than once daily). The primary endpoints assessed adverse drug reactions (ADRs), local tolerability, and systemic glycopyrronium exposure. Changes in sweat production, PAHH severity, and quality of life were assessed in all patients. Results: Two patients experienced mild ADRs (dry eye and increased conjugated bilirubin in one patient each); no serious adverse events occurred. All 40 evaluable patients had a skin reaction score of 0 throughout treatment. Total sweat production decreased significantly from baseline to day 29 ( p < 0.001) and day 57 ( p < 0.001). Patient‐rated hyperhidrosis severity (PRHS) and quality of life, assessed using the Children's Dermatology Life Quality Index (CDLQI), also improved significantly at both time points (all p < 0.001). Conclusions: 1% GPB cream showed favorable safety and tolerability and improved clinical outcomes in adolescents with severe PAHH, consistent with findings in adults.


  • Open Access

    Longitudinal validity of the Hyperhidrosis Quality of Life Index (HidroQoL©) in a phase IIIb clinical trial population with hyperhidrosis: responsiveness and meaningful change

    by Theresa Donhauser, Michaela Gabes, Clarissa Masur, Paul Kamudoni, Sam Salek, Christoph Abels, Christian Apfelbacher

    The Hyperhidrosis Quality of Life Index (HidroQoL ©) is a well-developed patient-reported outcome measure assessing the quality of life (QoL) impacts in hyperhidrosis, which has proven very good measurement properties, such as structural validity and internal consistency. We aimed to investigate responsiveness over time and estimate values for meaningful within-person change (MWPC) towards symptom improvement for different measurement time points (4 and 12 weeks), extending the existing validity evidence in patients with primary axillary hyperhidrosis. Data (from a phase IIIb clinical trial) was collected at baseline, week 4, week 8, week 12, week 28, week 52, and week 72. For the assessment of responsiveness, HidroQoL change scores were correlated with corresponding change scores of the Hyperhidrosis Disease Severity Scale (HDSS), the Dermatology Life Quality Index (DLQI), and the gravimetric sweat production based on a-priori formulated hypotheses. Furthermore, it was tested whether the different HDSS change score groups differed significantly from each other over time and whether the HidroQoL was sensitive towards these group differences over time. This was extended by the calculation of matched-pair tests and effect sizes to test significance for each change group separately. For the estimation of MWPC thresholds towards symptom improvement, different anchor-based and integrated approaches were used. In total, the sample was composed of 357 patients with primary axillary hyperhidrosis. For the assessment of responsiveness, 5 out of 14 a-priori hypotheses regarding the correlation of the change scores could be confirmed, whereas the rejected hypotheses only marginally differed from the expected values. Furthermore, regarding responsiveness, the HidroQoL showed sensitivity towards symptom improvement at each measurement time point. Effect sizes were large as expected (d ≥ 0.806). MWPC thresholds towards symptom improvement were proposed for two measurement time points: 5 (week 4) and 6 (week 12). Increasing MWPC values over time were observed. This study extends the evidence for the longitudinal validity of the HidroQoL up to 72 weeks and proposed MWPC thresholds for different time intervals (4 and 12 weeks) after baseline, aiding interpretability. Results concur with findings from previous validation studies.


  • What do Hyperhidrosis Quality of Life Index (HidroQoL©) scores mean? Transferring science into practice by establishing a score banding system

    by Theresa Donhauser, Michaela Gabes, Ebru Özkan, Clarissa Masur, Paul Kamudoni, Sam Salek, Christoph Abels, Christian Apfelbacher

    Background: The Hyperhidrosis Quality of Life Index (HidroQoL©) is a measure of quality of life (QoL) impacts in hyperhidrosis (HH). Objectives: We aimed to establish score banding systems for the HidroQoL total score for specific contexts representing different severity/impact categories by using the Dermatology Life Quality Index (DLQI) and the Hyperhidrosis Disease Severity Scale (HDSS) as anchors, including data from 357 patients from a phase III clinical trial. Methods: We used the HDSS, the established DLQI score bands and two single items (items 5 and 7) of the DLQI as anchors for the creation of banding systems for the HidroQoL. These anchors were chosen via consensus among an expert group according to relevance to patient experience. Due to the distribution of the HDSS and the single DLQI item 7, receiver operating characteristic curves were computed in order to create an optimal cut-off value of the HidroQoL total score. For the DLQI banding system and the single DLQI item 5, we created a banding system for the HidroQoL based on the distribution of their different categories. Results: A score of 30 and greater is proposed as the cut-off value for sweating that ‘always interferes in daily activities’, based on the HDSS as anchor. In terms of overall skin QoL effects, score bands of 0–6, 7–18, 19–25, 26–32 and 33–36 represent ‘no effect’, ‘small effect’, ‘moderate effect’, ‘very large effect’ and ‘extremely large effect’ on the patient’s life, respectively. Conclusions: In this study, we propose different banding systems for four different contexts: skin-specific QoL (DLQI banding), HH severity (HDSS), working and studying (single DLQI item 7) and social and leisure activities (single DLQI item 5). These banding systems and cut-off values can be used in clinical research and practice to place the patients in different severity categories.


  • Open Access

    Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial

    by Rolf‐Markus Szeimies, Christoph Abels, Ana Kilic, Hubert Reich, Birgit Berger, Erik Schulze Zur Wiesche, Katharina Schramm, Leonie Litzka, Susanne Heimstaedt‐Muskett, Clarissa Masur

    Background: Primary axillary hyperhidrosis (PAHH) strongly affects the patient's quality of life. To date, topical treatment options are limited. One percent glycopyrronium bromide (GPB) showed promising efficacy and safety in a pivotal 4‐week Phase 3a study.Objectives: To assess efficacy and safety of topical 1% GPB cream in patients with severe PAHH in a long‐term study of 72 weeks versus baseline.Methods: This was a long‐term, open‐label, Phase 3b trial for 72 weeks including 518 patients with severe PAHH. Patients were treated with 1% GPB cream once daily for 4 weeks, followed by a flexible dosing scheme (min. twice per week, max. once daily). Primary endpoint was the absolute change in sweat production from baseline to week 12. Further study endpoints included assessment of the severity of PAHH and the impact on quality of life.Results: Total median sweat production decreased by 119.30 mg (−65.6%, both median) until week 12. Absolute change in sweat production from baseline to week 12 in logarithmic values was statistically significant (p < 0.0001). Patients' quality of life was improved at all study time points compared to baseline, as assessed by Hyperhidrosis Quality of Life Index and Dermatology Life Quality Index (p < 0.0001). Treatment was safe and locally well‐tolerated with only few mild to moderate adverse drug reactions (ADRs). Dry mouth and application site erythema were the most common reported ADRs.Conclusions: Treatment with 1% GPB cream over 72 weeks significantly reduces sweat production and improves quality of life in patients with severe PAHH. One percent GPB cream is well‐tolerated and provides an effective treatment option for long‐term use in patients with severe PAHH.


  • Open Access

    Burden of disease: assessing quality-of-life impacts in hyperhidrosis

    by Michaela Gabes, Theresa Donhauser, Gesina Kann, Clarissa Masur, Christian Apfelbacher

    Dear Editor, Hyperhidrosis (HH) is a chronic disease caused by a dysregulation of the sympathetic nervous system, which leads to excessive sweating that exceeds the physiological needs for thermoregulation.1,2 Although HH is a common disease that restricts patients in their daily life, there is a lack of research concerning the burden of this disease. The Dermatology Life Quality Index (DLQI) assesses quality of life (QoL) in patients affected by different dermatological conditions.3 Therefore, the DLQI can be used to capture the burden of HH in affected patients. In this study, we performed a secondary analysis of clinical trial data to explore the QoL impact caused by severe primary axillary HH.


  • Pharmacokinetic profile data of glycopyrronium bromide 1% cream beyond 2 weeks are important: reply from the authors

    by C. Abels, M. Soeberdt, A. Kilic, H. Reich, U. Knie, C. Masur, R.‐M. Szeimies

    Gregoriou et al ask for systemic PK data beyond 2 weeks following the topical application of glycopyrronium bromide (GPB) containing cream for treatment of primary axillary hyperhidrosis referring to another recently approved glycopyrronium tosylate (GPT) containing topical product.

  • Open Access

    A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*

    by C. Abels, M. Soeberdt, A. Kilic, H. Reich, U. Knie, C. Jourdan, K. Schramm, S. Heimstaedt‐Muskett, C. Masur, R.‐M. Szeimies

    Background Effective topical treatment options for patients with primary axillary hyperhidrosis are limited. Recent phase 1 trial showed promising results regarding efficacy and safety for topical cream containing glycopyrronium bromide (GPB). Objective To assess efficacy, safety and tolerability of a 4‐week topical treatment with 1% GPB cream in subjects with primary axillary hyperhidrosis compared to placebo. Methods 171 patients (84 placebo; 87 1% GPB) with primary axillary hyperhidrosis were included in this 4 week, multicenter, randomised, double‐blind, placebo‐controlled Phase 3a part of the pivotal study. Sweat production was measured by gravimetry. Patients rated disease impact using the Hyperhidrosis Disease Severity Scale (HDSS) and Hyperhidrosis Quality of Life Index (HidroQoL©). Results Absolute change in sweat production from baseline to day 29 in logarithmic values was significantly larger in the 1% GPB group than in the placebo group (p=0.0038). The improvement in HidroQoL© exceeded minimal clinically important difference of 4. The proportion of responders was two‐fold higher than for placebo for sweat reduction, HDSS and HidroQoL© (‐197.08 mg GPB vs. ‐83.49 mg placebo; 23% GPB vs 11.9% placebo and 59.8% GPB vs. 26.2% placebo respectively). Treatment was safe, most TEAEs were mild or moderate and transient. Local tolerability was very good with 9.2% of patients having only mild or moderate application site reactions. The most reported ADR was dry mouth (16.1%), an expected anticholinergic effect of the treatment. Conclusion 1% GPB cream may provide an effective new treatment option exhibiting a good safety profile for patients with primary axillary hyperhidrosis. The long‐term open‐label part (Phase 3b) is ongoing.


  • Open Access

    Skin barrier integrity is enhanced after topical application of emulsions with an acidic pH

    by Ehrhardt Proksch, Soeren Merker, Sabine Mueller-Roehr, Claudia Neumann, Clarissa Masur, Ana Kilic, Christoph Abels

    The pH of the stratum corneum is slightly acidic (mean 4.9) and tightly regulated. This is important for antimicrobial defense and the formation of the physical barrier. The acidic pH inhibits the growth of pathogenic Staphylococcus aureus and enables optimal activity of enzymes for lipid synthesis, epidermal differentiation and desquamation. Here we asked whether topical

  • 316 Skin barrier function and integrity changes after topical application of emulsions with different pH

    by E. Proksch, S. Merker, S. Müller-Röhr, C. Neumann, H. Reich, C. Masur, A. Kilic, C. Abels

  • Open Access

    Efficacy of hydrophilic or lipophilic emulsions containing Echinacea purpurea extract in treatment of different types of pruritus

    by Ana Kilic, Anastasia Harder, Hubert Reich, Ulrich Knie, Clarissa Masur, Christoph Abels

    Background: Pruritus reduces quality of life and may occur at different sites of the body. To alleviate pruritus, lipid replenishing and rehydration of the skin is often unsatisfactory. Thus, products with additional antipruritic effects are needed. Objectives: Antipruritic effects and cosmetic properties of two different emulsions, water-in-oil (w/o) or oil-in-water (o/w), and a shampoo containing a lipophilic Echinacea purpurea root extract (Ec.-extract) were assessed in adults suffering from pruritus. Methods: Adults (n = 55) with pruritus of the body applied a w/o emulsion for 2 weeks. In a separate study, adults (n = 33) with a pruritic scalp applied an o/w-emulsion for 4 weeks. In a third study, shampoo (n = 34) was applied for 4 weeks. Objective (erythema, dryness, and papules) and subjective (intensity, duration, and burden of pruritus) parameters were assessed. Results: Treatment with the w/o emulsion significantly reduced erythema and dryness (P < 0.0001) as well as pruritus (in 93% of participants) on the body. Treatment with the o/w-emulsion on the scalp significantly (P < 0.0001) reduced objective (erythema in 61% and dryness in 85% of participants) and subjective (85% of participants had reduced pruritus) parameters. Similar results in reduction of dryness (76% of participants) and pruritus (70 % of participants) were seen after 4 weeks of shampoo use. Conclusion: Independent from the type of emulsion (w/o or o/w), cosmetic products containing a proprietary Ec.-extract significantly reduced objective and subjective parameters in adults suffering from acute or chronic pruritus exhibiting excellent tolerability.